Eli Lilly and CompanyvsPROCEPT BioRobotics

LLY and PRCT stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,415.55

Value $1.34T

-1.13%
LLY's page

PRCT

PROCEPT BioRobotics Corporation

$23.78

Value $1.3B

+1.02%
PRCT's page

Eli Lilly and Company (LLY) has a market value of $1.34T and PROCEPT BioRobotics (PRCT) $1.3B. Over the last year, with dividends, LLY moved +38.9% and PRCT -19.9%. Dividend yield: LLY 0.45%, PRCT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.34T

    PRCT$1.3B

    LLY is 996 times PRCT

  • Revenue, 12 months

    LLY$86.5B

    PRCT$352M

    LLY is 245 times PRCT

  • Net income, 12 months

    LLY$27.6B

    PRCT-$115M

  • Operating margin

    LLY–

    PRCT-33.6%

  • ROIC

    LLY35.5%

    PRCT-23.1%

    58.6 points apart

  • P/E

    LLY48.4

    PRCT–

  • Dividend yield

    LLY0.4%

    PRCT0.0%

    0.5 points apart

  • 5-year return

    LLY+473.5%

    PRCT-45.3%

    518.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+473.5%

PRCT-45.3%

20040060020222023202420252026
Returns by period
PeriodLLYWith dividendsPRCTWith dividends
1 year since November 14, 2025+38.9%Price +38.1%-19.9%Price -19.9%
3 years since November 17, 2023+144.0%+34.6% a yearPrice +139.2%-28.1%-10.4% a yearPrice -28.1%
5 years since November 16, 2021+473.5%+41.8% a yearPrice +449.3%-45.3%-11.4% a yearPrice -45.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyPRCTPROCEPT BioRobotics

Valuation

LLYPRCT
Valuation
Price$1,415.55$23.78
Market value$1.34T$1.3B
Enterprise value (EV)$1.38T$1.2B
P/E48.4–
P/E, 5-year median49.9–
P/B33.24.1
EV/EBIT39.7–
Free cash flow yield1.5%–

Results and growth

LLYPRCT
Results and growth
Revenue, 12 months$86.5B$352M
Net income, 12 months$27.6B-$115M
Free cash flow, 12 months$19.7B-$85M
Earnings per share, 12 months$30.81-$2.02
Revenue growth, year on year44.7%37.2%
Revenue growth a year, past+21.6%over 5 years+109.0%over 5 years
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYPRCT
Margins and returns on capital
Gross margin83.6%64.7%
Operating margin–-33.6%
Net margin31.9%-32.6%
ROIC35.5%-23.1%
ROE88.6%-32.6%

Balance sheet

LLYPRCT
Balance sheet
Cash$4.9B$218M
Total debt$49.5B$77M
Net debt / EBITDA1.2–
Interest cover38.9×-34.7×

Dividends and buybacks

LLYPRCT
Dividends and buybacks
Dividend yield0.4%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or PRCT

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or PROCEPT BioRobotics?

By market value, Eli Lilly and Company ($1.34T) is about 995.8 times PROCEPT BioRobotics ($1.3B), at today's prices.

How did LLY and PRCT stock do over the last 5 years?

Since November 16, 2021, LLY's price moved +449.3% and PRCT's -45.3%. With dividends: LLY +473.5% (+41.8% a year), PRCT -45.3% (-11.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or PRCT?

The dividend yield at today's price is 0.45% for Eli Lilly and Company and none for PROCEPT BioRobotics. Over the last twelve months they paid $6.34 and – per share.

Which has the higher profit margins, Eli Lilly and Company or PROCEPT BioRobotics?

Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and -32.6% for PROCEPT BioRobotics, and the operating margin – and -33.6%. Revenue was $86.5B and $352M.

Which is the better investment, Eli Lilly and Company or PROCEPT BioRobotics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.